Keyword search (4,163 papers available)

"nica" Keyword-tagged Publications:

Title Authors PubMed ID
1 Synthesis and Characterization of CNC/CNF/rGO Composite Films for Advanced Functional Applications Ramezani G; Stiharu I; van de Ven TGM; Ramezani H; Nerguizian V; 41900273
ENCS
2 Towards user-centered interactive medical image segmentation in VR with an assistive AI agent Spiegler P; Harirpoush A; Xiao Y; 41509996
ENCS
3 Preprocessing narrative texts in electronic medical records to identify hospital adverse events: A scoping review Jafarpour H; Wu G; Cheligeer CK; Yan J; Xu Y; Southern DA; Eastwood CA; Zeng Y; Quan H; 41072367
ENCS
4 The PREVENT-AD cohort: Accelerating Alzheimer s disease research and treatment in Canada and beyond Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Fajardo Valdez A; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Strikwerda-Brown C; Tardif CL; Gauthier CJ; Descoteaux M; Dadar M; Vachon-Presseau É; Baril AA; Ducharme S; Montembeault M; Geddes MR; Soucy JP; Rajah N; Laforce R; Bocti C; Davatzikos C; Bellec L; Rosa-Neto P; Baillet S; Evans AC; Collins DL; Chakravarty MM; Blennow K; Zetterbe 41020412
SOH
5 The PREVENT-AD cohort: accelerating Alzheimer s disease research and treatment in Canada and beyond Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Valdez AF; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Strikwerda-Brown C; Tardif CL; Gauthier CJ; Descoteaux M; Dadar M; Vachon-Presseau É; Baril AA; Ducharme S; Montembeault M; Geddes MR; Soucy JP; Rajah N; Laforce R; Bocti C; Davatzikos C; Bellec L; Rosa-Neto P; Baillet S; Evans AC; Collins DL; Chakravarty MM; Blennow K; Zetterberg H; S 40778177
PSYCHOLOGY
6 Unraveling "Feeling Bad" in a Non-Western Culture: Achievement Emotions in Japanese Medical Students Nomura O; Sunohara M; Akatsu H; Wiseman J; Lajoie SP; 40625926
PSYCHOLOGY
7 Exosome Innovations in Ophthalmology and Sjögren s Syndrome Wu KY; Dave A; Nirwal GK; Giunta M; Nguyen VDH; Tran SD; 40360847
CONCORDIA
8 Utilizing large language models for detecting hospital-acquired conditions: an empirical study on pulmonary embolism Cheligeer C; Southern DA; Yan J; Wu G; Pan J; Lee S; Martin EA; Jafarpour H; Eastwood CA; Zeng Y; Quan H; 40105654
ENCS
9 Automated abdominal aortic calcification scoring from vertebral fracture assessment images and fall-associated hospitalisations: the Manitoba Bone Mineral Density Registry Sim M; Gebre AK; Dalla Via J; Reid S; Jozani MJ; Kimelman D; Monchka BA; Gilani SZ; Ilyas Z; Smith C; Suter D; Schousboe JT; Lewis JR; Leslie WD; 40080298
ENCS
10 A synthetic model of bioinspired liposomes to study cancer-cell derived extracellular vesicles and their uptake by recipient cells López RR; Ben El Khyat CZ; Chen Y; Tsering T; Dickinson K; Bustamante P; Erzingatzian A; Bartolomucci A; Ferrier ST; Douanne N; Mounier C; Stiharu I; Nerguizian V; Burnier JV; 40069225
ENCS
11 Web-enhanced return-to-work coordination for employees with common mental disorders: reduction of sick leave duration and relapse Corbière M; Mazaniello-Chézol M; Lecomte T; Guay S; Panaccio A; Giguère CÉ; 39966766
PSYCHOLOGY
12 Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Collins DL; Dadar M; DeMarco ML; Ducharme S; Duchesne S; Einstein G; Fisk JD; Gawryluk JR; Grossman L; Ismail Z; Itzhak I; Joshi M; Harrison A; Kroger E; Kumar S; Laforce R; Lanctot KL; Lau M; Lee L; Masellis M; Massoud F; Mitchell SB; Montero-Odasso M; Myers Barnett K; Nygaard HB; Pasternak SH; Peters J; Rajah MN; Robillard JM; Rockwood K; Rosa-Neto P; Seitz DP; Soucy JP; Trenaman SC; Wellington CL; Zadem A; Chertkow H; 39893139
CONCORDIA
13 Leveraging Personal Technologies in the Treatment of Schizophrenia Spectrum Disorders: Scoping Review D' Arcey J; Torous J; Asuncion TR; Tackaberry-Giddens L; Zahid A; Ishak M; Foussias G; Kidd S; 39348196
PSYCHOLOGY
14 Microfluidic Wound-Healing Assay for Comparative Study on Fluid Dynamic, Chemical and Mechanical Wounding on Microglia BV2 Migration Yazdanpanah Moghadam E; Sonenberg N; Packirisamy M; 39203655
ENCS
15 "How do we do that?" An analysis of TikToks by lesbians over age 30 representing sexual identity, lived experience over time, and solidarity Jamet-Lange H; Duguay S; 38907626
CONCORDIA
16 Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22 McComb S; Arbabi-Ghahroudi M; Hay KA; Keller BA; Faulkes S; Rutherford M; Nguyen T; Shepherd A; Wu C; Marcil A; Aubry A; Hussack G; Pinto DM; Ryan S; Raphael S; van Faassen H; Zafer A; Zhu Q; Maclean S; Chattopadhyay A; Gurnani K; Gilbert R; Gadoury C; Iqbal U; Fatehi D; Jezierski A; Huang J; Pon RA; Sigrist M; Holt RA; Nelson BH; Atkins H; Kekre N; Yung E; Webb J; Nielsen JS; Weeratna RD; 38596311
BIOLOGY
17 Brain PET Imaging in Small Animals: Tracer Formulation, Data Acquisition, Image Reconstruction, and Data Analysis Bdair H; Kang MS; Ottoy J; Aliaga A; Kunach P; Singleton TA; Blinder S; Soucy JP; Leyton M; Rosa-Neto P; Kostikov A; 38006502
PERFORM
18 The impact of COVID-19 on the lives of Canadians with and without non-communicable chronic diseases: results from the iCARE Study Deslauriers F; Gosselin-Boucher V; Léger C; Vieira AM; Bacon SL; Lavoie KL; 37884921
HKAP
19 Assessing pragmatics in early childhood with the Language Use Inventory across seven languages Pesco D; O' Neill DK; 37408974
EDUCATION
20 Impact Behaviour of Steel-Fibre-Reinforced Alkali-Activated Slag Concrete Exposed to Elevated Temperatures Abubakr A; Soliman A; 37297228
ENCS
21 How to present work productivity loss results from clinical trials for patients and caregivers? A mixed methods approach L' Heureux J; McTaggart-Cowan H; Johns G; Chen L; Steiner T; Tocher P; Sun H; Zhang W; 37276772
JMSB
22 Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease Nayak SS; Naidu A; Sudhakaran SL; Vino S; Selvaraj G; 37109050
CHEMBIOCHEM
23 The association between information and communication technologies, loneliness and social connectedness: A scoping review Petersen B; Khalili-Mahani N; Murphy C; Sawchuk K; Phillips N; Li KZH; Hebblethwaite S; 37034933
PSYCHOLOGY
24 Identifying climate change refugia for South American biodiversity Sales LP; Pires MM; 36919472
BIOLOGY
25 Electroencephalographic characteristics of children and adolescents with chronic musculoskeletal pain Ocay DD; Teel EF; Luo OD; Savignac C; Mahdid Y; Blain-Moraes S; Ferland CE; 36601627
HKAP
26 Double-Bind of Recruitment of Older Adults Into Studies of Successful Aging via Assistive Information and Communication Technologies: Mapping Review Khalili-Mahani N; Sawchuk K; 36563033
CONCORDIA
27 Numerical-Experimental Analysis toward the Strain Rate Sensitivity of 3D-Printed Nylon Reinforced by Short Carbon Fiber Vanaei HR; Magri AE; Rastak MA; Vanaei S; Vaudreuil S; Tcharkhtchi A; 36556527
ENCS
28 Patient and family engagement in patient care and research in Canadian intensive care units: a national survey Burns KEA; McDonald E; Debigaré S; Zamir N; Vasquez M; Piche-Ayotte M; Oczkowski S; 36344874
BIOLOGY
29 Assessing Physician's Motivational Communication Skills: 5-Step Mixed Methods Development Study of the Motivational Communication Competency Assessment Test Gosselin Boucher V; Bacon S; Voisard B; Dragomir AI; Gemme C; Larue F; Labbé S; Szczepanik G; Corace K; Campbell T; Vallis M; Garber G; Rouleau C; Diodati JG; Rabi D; Sultan S; Lavoie K; 35749167
HKAP
30 The Social Lives of Infectious Diseases: Why Culture Matters to COVID-19 Bayeh R; Yampolsky MA; Ryder AG; 34630195
PSYCHOLOGY
31 Persuasive Features of Scientific Explanations: Explanatory Schemata of Physical and Psychosocial Phenomena Jordan Richard Schoenherr 34552522
PSYCHOLOGY
32 Relationships between Employees&#39, Identifications and Citizenship Behavior in Work Groups: The Role of the Regularity and Intensity of Interactions Sidorenkov AV; Borokhovski EF; 34206317
CSLP
33 COVID-19 Experiences and Social Distancing: Insights From the Theory of Planned Behavior Frounfelker RL; Santavicca T; Li ZY; Miconi D; Venkatesh V; Rousseau C; 34074154
CONCORDIA
34 Proper Orthogonal Decomposition Analysis of the Flow Downstream of a Dysfunctional Bileaflet Mechanical Aortic Valve. Darwish A, Di Labbio G, Saleh W, Kadem L 33469847
ENCS
35 Socio-demographic, social, cognitive, and emotional correlates of adherence to physical distancing during the COVID-19 pandemic: a cross-sectional study. Gouin JP, MacNeil S, Switzer A, Carrese-Chacra E, Durif F, Knäuper B 33464556
CONCORDIA
36 Pantomime (Not Silent Gesture) in Multimodal Communication: Evidence From Children's Narratives. Marentette P, Furman R, Suvanto ME, Nicoladis E 33329222
PSYCHOLOGY
37 Depression prevalence based on the Edinburgh Postnatal Depression Scale compared to Structured Clinical Interview for DSM DIsorders classification: Systematic review and individual participant data meta-analysis Lyubenova A; Neupane D; Levis B; Wu Y; Sun Y; He C; Krishnan A; Bhandari PM; Negeri Z; Imran M; Rice DB; Azar M; Chiovitti MJ; Saadat N; Riehm KE; Boruff JT; Ioannidis JPA; Cuijpers P; Gilbody S; Kloda LA; Patten SB; Shrier I; Ziegelstein RC; Comeau L; Mitchell ND; Tonelli M; Vigod SN; Aceti F; Barnes J; Bavle AD; Beck CT; Bindt C; Boyce PM; Bunevicius A; Chaudron LH; Favez N; Figueiredo B; Garcia-Esteve L; Giardinelli L; Helle N; Howard LM; Kohlhoff J; Kusminskas L; Kozinszky Z; Lelli L; Leonardou AA; Meuti V; Radoš SN; García PN; Pawlby SJ; Quispel C; Robertson-Blackmore E; Rochat TJ; Sharp DJ; Siu BWM; Stein A; Stewart RC; Tadinac M; Tandon SD; Tendais I; Töreki A; Torres-Giménez A; Tran TD; Trevillion K; Turner K; Vega-Dienstmaier JM; Benedetti A; Thombs BD; 33089942
CONCORDIA
38 What Media Helps, What Media Hurts: A Mixed Methods Survey Study of Coping with COVID-19 Using the Media Repertoire Framework and the Appraisal Theory of Stress Pahayahay A; Khalili-Mahani N; 32701459
PERFORM
39 The Value in Science-Art Partnerships for Science Education and Science Communication. Zaelzer C 32616625
CONCORDIA
40 High-risk environments promote chemical disturbance signalling among socially familiar Trinidadian guppies. Crane AL, Feyten LEA, Ramnarine IW, Brown GE 32296954
BIOLOGY
41 Functional Characterization of Clinical Isolates of the Opportunistic Fungal Pathogen Aspergillus nidulans. Bastos RW, Valero C, Silva LP, Schoen T, Drott M, Brauer V, Silva-Rocha R, Lind A, Steenwyk JL, Rokas A, Rodrigues F, Resendiz-Sharpe A, Lagrou K, Marcet-Houben M, Gabaldón T, McDonnell E, Reid I, Tsang A, Oakley BR, Loures FV, Almeida F, Huttenlocher A, Keller NP, Ries LNA, Goldman GH 32269156
CSFG
42 An international Delphi consensus study to define motivational communication in the context of developing a training program for physicians. Dragomir AI, Boucher VG, Bacon SL, Gemme C, Szczepanik G, Corace K, Campbell TS, Vallis MT, Garber G, Rouleau C, Rabi D, Diodati JG, Ghali W, Lavoie KL 32145022
HKAP
43 The non-aromatizable androgen dihydrotestosterone (DHT) facilitates sexual behavior in ovariectomized female rats primed with estradiol. Maseroli E, Santangelo A, Lara-Fontes B, Quintana GR, Mac Cionnaith CE, Casarrubea M, Ricca V, Maggi M, Vignozzi L, Pfaus JG 32087523
PSYCHOLOGY
44 Exploring the use of smartphones and tablets among people with visual impairments: Are mainstream devices replacing the use of traditional visual aids? Martiniello N, Eisenbarth W, Lehane C, Johnson A, Wittich W 31697612
PSYCHOLOGY
45 Aromatization Is Not Required for the Facilitation of Appetitive Sexual Behaviors in Ovariectomized Rats Treated With Estradiol and Testosterone. Jones SL, Rosenbaum S, Gardner Gregory J, Pfaus JG 31447629
CSBN
46 Glass ionomer cements with enhanced mechanical and remineralizing properties containing 45S5 bioglass-ceramic particles. Zandi Karimi A, Rezabeigi E, Drew RAL 31174045
ENCS
47 Some Metabolites Act as Second Messengers in Yeast Chronological Aging. Mohammad K, Dakik P, Medkour Y, McAuley M, Mitrofanova D, Titorenko VI 29543708
BIOLOGY
48 Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheimer’s Disease Neuroimaging Initiative 29396637
PERFORM
49 To Each Stress Its Own Screen: A Cross-Sectional Survey of the Patterns of Stress and Various Screen Uses in Relation to Self-Admitted Screen Addiction Khalili-Mahani N; Smyrnova A; Kakinami L; 30938685
PERFORM

 

Title:The PREVENT-AD cohort: Accelerating Alzheimer s disease research and treatment in Canada and beyond
Authors:Villeneuve SPoirier JBreitner JCSTremblay-Mercier JRemz JRaoult JMYakoub YGallego-Rudolf JQiu TFajardo Valdez AMohammediyan BJavanray MMetz ASanami SOurry VWearn APastor-Bernier AEdde MGonneaud JStrikwerda-Brown CTardif CLGauthier CJDescoteaux MDadar MVachon-Presseau ÉBaril AADucharme SMontembeault MGeddes MRSoucy JPRajah NLaforce RBocti CDavatzikos CBellec LRosa-Neto PBaillet SEvans ACCollins DLChakravarty MMBlennow KZetterbe
Link:https://pubmed.ncbi.nlm.nih.gov/41020412/
DOI:10.1002/alz.70653
Publication:Alzheimer s & dementia : the journal of the Alzheimer s Association
Keywords:biomarkersclinical progressioncognitiondata repositoryneuroimagingpreclinical
PMID:41020412 Category: Date Added:2025-09-29
Dept Affiliation: SOH
1 StoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, Quebec, Canada.
2 Department of Psychiatry, McGill University, Montréal, Quebec, Canada.
3 McConnell Brain Imaging Center, Montreal Neurological Institute, McGill University, Montréal, Quebec, Canada.
4 Cerebral Imaging Centre, Douglas Mental Health University Institute, McGill University, Montréal, Quebec, Canada.
5 Integrated Program in Neuroscience, McGill University, Montréal, Quebec, Canada.
6 Research Center of the CIUSSS-NIM, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada.
7 Department of Medicine, Faculty of Medicine, Université de Montréal, Montréal, Quebec, Canada.
8 Department of Physics, Concordia University, Montréal, Quebec, Canada.
9 Department of Neurology and Neurosurgery, McGill University, Montréal, Quebec, Canada.
10 Faculté des sciences, Département d'informatique, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
11 Normandie Univ, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", NeuroPresage Team, GIP Cyceron, Caen, France.
12 School of Psychological Science, The University of Western Australia, Perth, Western Australia, Australia.
13 Department Biomedical Engineering, McGill University, Montréal, Quebec, Canada.
14 Centre ÉPIC, Montreal Heart Institute, Montréal, Quebec, Canada.
15 School of Health, Concordia University, Montréal, Quebec, Canada.
16 Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, Quebec, Canada.
17 Department of Anesthesia, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
18 Alan Edwards Center for Research on Pain, McGill University, Montreal, Quebec, Canada.
19 Department of Psychology, Toronto Metropolitan University, Toronto, Ontario, Canada.
20 Clinique interdisciplinaire de mémoire, CHU de Québec affilié à l'Université Laval, Québec, Quebec, Canada.
21 Division of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
22 AI2D Center for AI and Data Science for Integrated Diagnostics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
23 Psychology Department, Université de Montréal, Montréal, Quebec, Canada.
24 Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, Quebec, Canada.
25 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
26 Clinical Neurochemistry Lab, Sahlgrenska University Hospital, Mölndal, Sweden.
27 Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.
28 Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, Anhui, P.R. China.
29 Department of Neurodegenerative Disease, University College London Institute of Neurology, London, UK.
30 UK Dementia Research Institute at UCL, London, UK.
31 Hong Kong Center for Neurodegenerative Diseases, InnoHK, Hong Kong, China.
32 Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
33 Department of Physiology and Pharmacology, Université de Montréal, Montréal, Quebec, Canada.
34 Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.

Description:

The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now been followed annually for more than 12 years (median follow-up 8.0 years, SD 3.1). Multimodal magnetic resonance imaging (MRI), genetic, neurosensory, clinical, cerebrospinal fluid, and cognitive data collected until 2017 on 348 participants who agreed to open sharing with the neuroscience community were already available. We now share a new release including 6 years of additional follow-up cognitive data, and additional MRI follow-ups, clinical progression, new longitudinal behavioral and lifestyle measures (questionnaires, actigraphy), longitudinal AD plasma biomarkers, amyloid-beta and tau positron emission tomography (PET), magnetoencephalography, as well as neuroimaging analytic measures from all MRI modalities. We describe the PREVENT-AD study, the data shared with the global research community, as well as the model we created to sustain longitudinal follow-ups while also allowing new innovative data collection. HIGHLIGHTS: The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is a single-site longitudinal study that started in 2011 with annual follow-up data collection on individuals at risk of Alzheimer's disease who were all cognitively normal at enrolment. All 387 participants were enrolled between 2011 and 2017 and 306 (79%) of these participants were still in the study as of December 2023. While the PREVENT-AD dataset was not originally planned to be shared with the global research community, 348 participants retrospectively consented for their data to be shared with researchers worldwide. The first release of data was in 2019. We now share a second release that includes 6 years of additional follow-up visits, information on clinical progression and novel cognitive, behavioral, genetic, plasma and neuroimaging (amyloid and tau positron emission tomography [PET], magnetoencephalography [MEG], and new magnetic resonance imaging [MRI] sequences) data. It also includes analytic outputs for neuroimaging modalities.





BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University